Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT00737685
Other study ID # KSPHO-SCT0401
Secondary ID
Status Active, not recruiting
Phase Phase 2
First received August 18, 2008
Last updated March 23, 2012
Start date January 2006
Est. completion date December 2012

Study information

Verified date March 2012
Source The Korean Society of Pediatric Hematology Oncology
Contact n/a
Is FDA regulated No
Health authority Korea: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

Anti-thymocyte globulin (ATG) has been used in severe aplastic anemia as a part of the conditioning regimen. Among the many kinds of ATG preparations, thymoglobulin had been found to be more effective in preventing GVHD and rejection of organ transplants. As the fludarabine based conditioning regimens without total body irradiation have been reported to be promising for BMT/PBSCT from alternative donors in SAA, thymoglobulin was added to fludarabine and cyclophosphamide conditioning to reduce GVHD and to allow good engraftment in UBMT/UPBSCT.


Description:

GVHD prophylaxis recommendation tacrolimus (0.03 mg/kg/day i.v. by continuous infusion from day -2 and taper with an oral form until 1 year after BMT/PBSCT) methotrexate (15 mg/m2 i.v. on days 1 and 10 mg/m2 i.v. on days 3, 6, 11)


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 30
Est. completion date December 2012
Est. primary completion date August 2012
Accepts healthy volunteers No
Gender Both
Age group N/A to 25 Years
Eligibility Inclusion Criteria:

- Diagnosis of severe aplastic anemia defined by any two or three peripheral blood criteria

- and either marrow criterion.

- Peripheral blood

1. Neutrophils < 0.5 x 109/l

2. Platelets < 20 x 109/l

3. Corrected reticulocytes < 1%

- Bone marrow

1. Severe hypocellularity (< 25%)

2. Moderate hypocellularity (25-30%) with hematopoietic cells representing < 30% of residual cells

- No prior hematopoietic stem cell transplantation.

- Age: no limits.

- Performance status: ECOG 0-2.

- Patients must be free of significant functional deficits in major organs, but the following eligibility criteria may be modified in individual cases.

1. Heart: a shortening fraction > 30%, ejection fraction > 45%.

2. Liver: total bilirubin < 2 × upper limit of normal; ALT < 3 × upper limit of normal.

3. Kidney: creatinine <2 × normal or a creatinine clearance (GFR) > 60 ml/min/1.73m2.

- Patients must lack any active viral infections or active fungal infection.

- Appropriate donor is available: Matched in 6/6 of A, B, DR loci.

- Patients (or one of parents if patients age < 19) should sign informed consent.

Exclusion Criteria:

- Pregnant or nursing women.

- Malignant or nonmalignant illness that is uncontrolled or whose control may be jeopardized by complications of study therapy.

- Psychiatric disorder that would preclude compliance.

- Congenital aplastic anemia including Fanconi anemia.

- Manipulated bone marrow.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
cyclophosphamide, fludarabine , thymoglobulin
cyclophosphamide (50 mg/kg once daily i.v. on days -9, -8, -7 & -6) fludarabine (30 mg/m2 once daily i.v. on days -5, -4, -3 & -2) thymoglobulin (2.5 mg/kg once daily i.v. on days -3, -2 & -1)

Locations

Country Name City State
Korea, Republic of Seoul National University Hospital Seoul

Sponsors (1)

Lead Sponsor Collaborator
The Korean Society of Pediatric Hematology Oncology

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary To evaluate the engraftment potential, incidence and severity of acute graft versus host disease,toxicity of conditioning regimen for UBMT in SAA. From Jan. 1. 2006 to Dec. 31. 2008. For 3 years. No
Primary To evaluate overall and EFS follow-up of 1 year after UBMT/PBSCT. From Jan. 1. 2006 to Dec. 31. 2008. For 3 years No
Secondary To evaluate chronic GVHD and immunologic recovery after UBMT/PBSCT. and the efficacy of UBMT/PBSCT before immuno-suppressive therapy with anti-thymocyte globulin in severe aplastic anemia and long term toxicity of non-TBI based conditioning From Jan. 1. 2006 to Dec. 31. 2008. For 3 years. No
See also
  Status Clinical Trial Phase
Completed NCT00997386 - Reduced Intensity Allogeneic PBSCT to Treat Hematologic Malignancies and Hematopoietic Failure States Phase 2
Completed NCT00975975 - Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer Phase 2
Terminated NCT00393380 - Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor Phase 2
Completed NCT00229619 - Rituximab to Treat Moderate Aplastic Anemia, Pure Red Cell Aplasia, or Diamond Blackfan Anemia Phase 2
Completed NCT00000603 - Cord Blood Stem Cell Transplantation Study (COBLT) Phase 2
Completed NCT00005682 - Aplastic Anemia Epidemiology: Incidence and Case-control N/A
Completed NCT00244010 - Partially Matched Stem Cell Transplantation for Patients With Refractory Severe Aplastic Anemia or Refractory Cytopenias N/A
Completed NCT00692926 - Unrelated Umbilical Cord Blood Transplantation Augmented With ALDHbr Umbilical Cord Blood Cells Phase 1
Recruiting NCT00399971 - Safety and Efficacy Study of Ex Vivo Immunotherapy for Treatment of Aplastic Anemia Phase 1/Phase 2
Completed NCT00683046 - T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies Phase 2
Completed NCT00922883 - A Pilot Study of the Thrombopoietin-Receptor Agonist Eltrombopag in Refractory Aplastic Anemia Patients Phase 2
Recruiting NCT00319878 - Sirolimus and Cyclosporine for Treatment-Resistant Aplastic Anemia Phase 1/Phase 2
Completed NCT00061763 - Study of Deferasirox in Iron Overload From Beta-thalassemia Unable to be Treated With Deferoxamine or Chronic Anemias Phase 2
Completed NCT00144729 - Conditioning Regimens for Patients With Severe Aplastic Anemia Transplanted With Marrow From an Unrelated Donor Phase 1/Phase 2
Completed NCT00000597 - Multi-Center Trial of Anti-Thymocyte Globulin in Treatment of Aplastic Anemia and Other Hematologic Disorders Phase 3
Recruiting NCT02773225 - Efficacy and Safety of Eltrombopag + CSA in Patients With Moderate Aplastic Anemia (EMAA) Phase 2/Phase 3
Terminated NCT03733249 - Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study Phase 1/Phase 2
Completed NCT00326417 - Fludarabine-based Conditioning for Severe Aplastic Anemia (BMT CTN 0301) Phase 1/Phase 2
Completed NCT00618969 - Peripheral Blood Stem Cell Transplantation (PBSCT)From Haploidentical Related Donors Phase 2
Completed NCT00578266 - Allogeneic Stem Cell Transplantation for Patients With Severe Aplastic Anemia Phase 1